Effect of L-carnitine therapy on patients in maintenance hemodialysis: A systematic review and meta-analysis

Journal of Nephrology

Volumn 27, Issue 3, 2014, Pages 317-329

  Yang, Shi Kun ^a   Xiao, Li ^a   Song, Pan Ai ^a   Xu, Xiaoxuan ^a   Liu, Fu You ^a   Sun, Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Effect; Hemodialysis; L Carnitine; Meta analysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; HEMOGLOBIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PLACEBO; TRIACYLGLYCEROL;

ANEMIA; ARTICLE; ASTHENIA; END STAGE RENAL DISEASE; FLU LIKE SYNDROME; HEADACHE; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; INFLAMMATION; META ANALYSIS; MUSCLE CRAMP; NUTRITION; OXIDATIVE STRESS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SYSTEMATIC REVIEW;

EID: 84901013879     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-013-0002-7     Document Type: Article

References (48)

1. Wolf AV, Remp DG, Kiley JE, Currie GD (1951) Artificial kidney function; kinetics of hemodialysis. J Clin Invest 30:1062-1070
2. de Mutsert R, Krediet RT (2006) Malnutrition, inflammation and atherosclerosis (MIA-syndrome) in dialysis patients. Ned Tijdschr Geneeskd 150:2023-2027
3. Miller B, Ahmad S (2003) A review of the impact of L-carnitine therapy on patient functionality in maintenance hemodialysis. Am J Kidney Dis 41:S44-S48
4. Chilcot J (2012) The importance of illness perception in endstage renal disease: associations with psychosocial and clinical outcomes. Semin Dial 25:59-64
5. Cerretelli P, Marconi C (1990) L-carnitine supplementation in humans. The effects on physical performance. Int J Sports Med 11:1-14
6. Arduini A, Bonomini M, Savica V, Amato A, Zammit V (2008) Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 120:149-156
7. Rodriguez-Segade S, Alonso de la Pena C, Paz M et al (1986) Carnitine concentrations in dialysed and undialysed patients with chronic renal insufficiency. Ann Clin Biochem 23:671-675
8. Calò LA, Vertolli U, Davis PA, Savica V (2012) L carnitine in hemodialysis patients. Hemodial Int 16:428-434
9. Review Manager (RevMan) [Computer program]. The Nordic Cochrane Centre. Version 5.1. The Cochrane Collaboration 2011, Copenhagen
10. Higgins JP. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration 2011. http:// www.cochrane-handbook.org
11. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558
12. Fatouros IG, Douroudos I, Panagoutsos S et al (2010) Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc 42:1809-1818
13. Ahmad S, Robertson HT, Golper TA et al (1990) Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912-918
14. Biolo G, Stulle M, Bianco F et al (2008) Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 23:991-997
15. Brass EP, Adler S, Sietsema KE et al (2001) Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 37:1018-1028
16. Chazot C, Blanc C, Hurot JM, Charra B, Jean G, Laurent G (2003) Nutritional effects of carnitine supplementation in hemodialysis patients. Clin Nephrol 59:24-30
17. Cibulka R, Racek J, Pikner R et al (2007) Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. Calcif Tissue Int 81:99-106
18. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yücel D (2006) Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 21:3211-3214
19. Emami Naini A, Moradi M, Mortazavi M et al (2012) Effects of oral L-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized, double-blinded, placebo-controlled trial. J Nutr Metab 2012:510483
20. Golper TA, Wolfson M, Ahmad S et al (1990) Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 38:904-911
21. Hakeshzadeh F, Tabibi H, Ahmadinejad M, Malakoutian T, Hedayati M (2010) Effects of L-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Ren Fail 32:1109-1114
22. Mitwalli AH, Al-Wakeel JS, Alam A et al (2005) L-carnitine supplementation in hemodialysis patients. Saudi J Kidney Dis Transpl 16:17-22
23. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S (2006) Results of a single blind, randomized, placebocontrolled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci 60:143-153
24. Sabry AA (2010) The role of oral L-carnitine therapy in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 21:454-459
25. Sakurabayashi T, Miyazaki S, Yuasa Y et al (2008) L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J 72:926-931
26. Savica V, Santoro D, Mazzaglia G et al (2005) L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 15:225-230
27. Shakeri A, Tabibi H, Hedayati M (2010) Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 14:498-504
28. Shojaei M, Djalali M, Khatami M, Siassi F, Eshraghian M (2011) Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 5:114-118
29. Signorelli SS, Fatuzzo P, Rapisarda F et al (2006) A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. Drugs Aging 23:263-270
30. Steiber AL, Davis AT, Spry L et al (2006) Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. JPEN J Parenter Enteral Nutr 30:10-15
31. Suchitra MM, Ashalatha VL, Sailaja E et al (2011) The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 22:1155-1159
32. Tabibi H, Hakeshzadeh F, Hedayati M, Malakoutian T (2011) Effects of L-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial. J Ren Nutr 21:485-491
33. Thomas S, Fischer FP, Mettang T, Pauli-Magnus C, Weber J, Kuhlmann U (1999) Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: a double-blind randomized trial. Am J Kidney Dis 34:678-687
34. Trovato GM, Iannetti E, Murgo AM, Carpinteri G, Catalano D (1998) Body composition and long-term levo-carnitine supplementation. Clin Ter 149:209-214
35. Weschler A, Aviram M, Levin M, Better OS, Brook JG (1984) High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 38:120-124
36. Mercadal L, Coudert M, Vassault A et al (2012) L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol 7:1836-1842
37. Bonomini M, Zammit V, Pusey CD, De Vecchi A, Arduini A (2011) Pharmacological use of L-carnitine in uremic anemia: has its full potential been exploited? Pharmacol Res 63:157-164
38. Hedayati SS (2006) Dialysis-related carnitine disorder. Semin Dial 19:323-328
39. Aleisa AM, Al-Majed AA, Al-Yahya AA et al (2007) Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 34:1252-1259
40. Mingorance C, Rodriguez-Rodriguez R, Justo ML, Herrera MD, de Sotomayor MA (2011) Pharmacological effects and clinical applications of propionyl-L-carnitine. Nutr Rev 69:279-290
41. Yu J, Ye J, Liu X, Han Y, Wang C (2011) Protective effect of Lcarnitine against H(2)O(2)-induced neurotoxicity in neuroblastoma (SH-SY5Y) cells. Neurol Res 33(7):708-716
42. Ribas GS, Biancini GB, Mescka C et al (2012) Oxidative stress parameters in urine from patients with disorders of propionate metabolism: a beneficial effect of L-carnitine supplementation. Cell Mol Neurobiol 32:77-82
43. Günal AI, Celiker H, Dönder E, Günal SY (1999) The effect of Lcarnitine on insulin resistance in hemodialysed patients with chronic renal failure. J Nephrol 12:38-40
44. Kitamura Y, Satoh K, Satoh T, Takita M, Matsuura A (2005) Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells. Nephrol Dial Transplant 20:981-984
45. Hurot JM, Cucherat M, Haugh M, Fouque D (2002) Effects of Lcarnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 13:708-714
46. Aslan D, Andersen MD, Gede LB et al (2012) Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest 72:14-22
47. Adamek G, Felix R, Guenther HL, Fleisch H (1987) Fatty acid oxidation in bone tissue and bone cells in culture. Characterization and hormonal influences. Biochem J 248:129-137
48. Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH (2011) Adult measures of general health and healthrelated quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken) 63(Suppl 11):S383-S412